Cardiac concentric remodelling induced by non-aromatizable (dihydro-)testosterone is antagonized by oestradiol in ovariectomized rats

Journal of Endocrinology

Volumn 189, Issue 3, 2006, Pages 485-491

  Tivesten, Åsa ^b   Bollano, E ^b   Nystrom H C ^a   Alexanderson, C ^b   Bergstrom G ^a   Holmang A ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ESTRADIOL; MESSENGER RNA; SOMATOMEDIN C; TESTOSTERONE;

ANDROGEN BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; DRUG ANTAGONISM; DRUG MECHANISM; ESTRADIOL BLOOD LEVEL; FEMALE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE REMODELING; HEART WEIGHT; M MODE ECHOCARDIOGRAPHY; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; TELEMETRY; TESTOSTERONE BLOOD LEVEL;

ANDROGENS; ANIMALS; DIHYDROTESTOSTERONE; ECHOCARDIOGRAPHY; ESTRADIOL; FEMALE; HEART; HEART VENTRICLES; INSULIN-LIKE GROWTH FACTOR I; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 33745262542     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.1.06722     Document Type: Article

References (31)

1. Babiker FA, De Windt LJ, van Eickels M, Thijssen V, Bronsaer RJ, Grohe C, van Bilsen M & Doevendans PA 2004 17 beta-estradiol antagonizes cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a guanylyl cyclase A receptor-cyclic guanosine monophosphate-dependent protein kinase pathway. Circulation 109 269-276.
2. Barrett-Connor E 2003 Clinical review 162: cardiovascular endocrinology 3: an epidemiologist looks at hormones and heart disease in women. Journal of Clinical Endocrinology and Metabolism 88 4031-4042.
3. Beyer ME, Yu G, Hanke H & Hoffmeister HM 2001 Acute gender-specific hemodynamic and inotropic effects of 17 beta-estradiol on rats. Hypertension 38 1003-1010.
4. Cotroneo MS, Wang J, Eltoum IA & Lamartiniere CA 2001 Sex steroid receptor regulation by genistein in the prepubertal rat uterus. Molecular and Cellular Endocrinology 173 135-145.
5. Fritz WA, Wang J, Eltoum IE & Lamartiniere CA 2002 Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate. Molecular and Cellular Endocrinology 186 89-99.
6. Hayward CS, Webb CM & Collins P 2001 Effect of sex hormones on cardiac mass. Lancet 357 1354-1356.
7. Hodgin JB & Maeda N 2002 Minireview: estrogen and mouse models of atherosclerosis. Endocrinology 143 4495-4501.
8. Isgaard J, Tivesten A, Friberg P & Bengtsson BA 1999 The role of the GH/ IGF-I axis for cardiac function and structure. Hormone Metabolism Research 31 50-54.
9. Lin MC, Rajfer J, Swerdloff RS & Gonzalez-Cadavid NF 1993 Testosterone down-regulates the levels of androgen receptor mRNA in smooth muscle cells from the rat corpora cavernosa via aromatization to estrogens. Journal of Steroid Biochemistry and Molecular Biology 45 333-343.
10. Liu PY, Death AK & Handelsman DJ 2003 Androgens and cardiovascular disease. Endocrine Reviews 24 313-340.
11. Marsh JD, Lehmann MH, Ritchie RE, Gwathmey JK, Green GE & Schiebinger RJ 1998 Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation 98 256-261.
12. Mendelsohn ME & Karas RH 2005 Molecular and cellular basis of cardiovascular gender differences. Science 308 1583-1587.
13. Nahrendorf M, Frantz S, Hu K, von zur Muhlen C, Tomaszewski M, Scheuermann H, Kaiser R, Jazbutyte V, Beer S, Bauer W et al. 2003 Effect of testosterone on post-myocardial infarction remodeling and function. Cardiovascular Research 57 370-378.
14. Nelson HD, Humphrey LL, Nygren P, Teutsch SM & Allan JD 2002 Postmenopausal hormone replacement therapy: scientific review. Journal of the American Medical Association 288 872-881.
15. Pawlush DG, Moore RL, Musch TI & Davidson WR Jr 1993 Echocardiographic evaluation of size, function, and mass of normal and hypertrophied rat ventricles. Journal of Applied Physiology 74 2598-2605.
16. Pelzer T, Jazbutyte V, Hu K, Segerer S, Nahrendorf M, Nordbeck P, Bonz AW, Muck J, Fritzemeier KH, Hegele-Hartung C et al. 2005 The estrogen receptor-alpha agonist 16 alpha-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats. Cardiovascular Research 67 604-612.
17. Sahn DJ, DeMaria A, Kisslo J & Weyman A 1978 Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58 1072-1073.
18. Schillaci G, Verdecchia P, Borgioni C, Ciucci A & Porcellati C 1998 Early cardiac changes after menopause. Hypertension 32 764-769.
19. Snyder PJ 2001 The role of androgens in women. Journal of Clinical Endocrinology and Metabolism 86 1006-1007.
20. Stover EP, Krishnan AV & Feldman D 1987 Estrogen down-regulation of androgen receptors in cultured human mammary cancer cells (MCF-7). Endocrinology 120 2597-2603.
21. Taylor RA, Cowin P, Couse JF, Korach KS & Risbridger GP 2006 17β-estradiol induces apoptosis in the developing rodent prostate independently of ERα or ERβ. Endocrinology 147 191-200.
22. Thum T & Borlak J 2002 Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB Journal 16 1537-1549.
23. Tivesten A, Bollano E, Caidahl K, Kujacic V, Sun XY, Hedner T, Hjalmarson A, Bengtsson BA & Isgaard J 2000 The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology 141 60-66.
24. Tivesten A, Moverare-Skrtic S, Chagin A, Venken K, Salmon P, Vanderschueren D, Savendahl L, Holmang A & Ohlsson C 2004 Additive protective effects of estrogen and androgen treatment on trabecular bone in ovariectomized rats. Journal of Bone Mineral Research 19 1833-1839.
25. Tsunoda K, Yamaguchi Y, Taguchi T, Doge K, Kato Y, Sato A & Keizo S 1999 Cardiovascular effects of dihydrotestosterone in rats. Legal Medicine (Tokyo) 1 95-104.
26. Vandenput L, Boonen S, Van Herck E, Swinnen JV, Bouillon R & Vanderschueren D 2002 Evidence from the aged orchidectomized male rat model that 17 beta-estradiol is a more effective bone-sparing and anabolic agent than 5 alpha-dihydrotestosterone. Journal of Bone Mineral Research 17 2080-2086.
27. van Eickels M, Grohe C, Cleutjens JP, Janssen BJ, Wellens HJ & Doevendans PA 2001 17 beta-estradiol attenuates the development of pressure-overload hypertrophy. Circulation 104 1419-1423.
28. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Bartoccini C, Santucci A, Santucci C, Reboldi G & Porcellad C 1995 Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. Journal of the American College of Cardiologists 25 871-878.
29. Verdecchia P, Reboldi G, Schillaci G, Borgioni C, Ciucci A, Telera MP, Santeusanio F, Porcellati C & Brunetti P 1999 Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation 100 1802-1807.
30. Wu FC & von Eckardstein A 2003 Androgens and coronary artery disease. Endocrine Reviews 24 183-217.
31. Yin FC, Spurgeon HA, Rakusan K, Weisfeldt ML & Lakatta EG 1982 Use of tibial length to quantify cardiac hypertrophy: application in the aging rat. American Journal of Physiology 243 H941-H947.